NASDAQ:CNAT - Conatus Pharmaceuticals Stock Price, Price Target & More

Conatus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNAT."

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) released its quarterly earnings results on Wednesday, May, 2nd. The biotechnology company reported ($0.17) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.17). The biotechnology company earned $9.74 million during the quarter, compared to the consensus estimate of $8.88 million. Conatus Pharmaceuticals had a negative net margin of 49.30% and a negative return on equity of 64.30%. View Conatus Pharmaceuticals' Earnings History.

Conatus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Conatus Pharmaceuticals.

6 Wall Street analysts have issued 1-year price targets for Conatus Pharmaceuticals' shares. Their predictions range from $4.30 to $20.00. On average, they expect Conatus Pharmaceuticals' stock price to reach $12.1414 in the next year. This suggests a possible upside of 190.5% from the stock's current price. View Analyst Ratings for Conatus Pharmaceuticals.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Conatus Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Conatus Pharmaceuticals saw a drop in short interest in June. As of June 29th, there was short interest totalling 1,612,627 shares, a drop of 32.0% from the June 15th total of 2,372,503 shares. Based on an average daily trading volume, of 809,565 shares, the short-interest ratio is presently 2.0 days. Approximately 6.1% of the company's stock are short sold. View Conatus Pharmaceuticals' Current Options Chain.

Some companies that are related to Conatus Pharmaceuticals include Merus (MRUS), Keryx Biopharmaceuticals (KERX), Depomed (DEPO), Magenta Therapeutics (MGTA), ArQule (ARQL), Arcus Biosciences (RCUS), Rigel Pharmaceuticals (RIGL), Stemline Therapeutics (STML), Aurinia Pharmaceuticals (AUPH), Evolus (EOLS), Cytokinetics (CYTK), Verastem (VSTM), ZEALAND PHARMA/S (ZEAL), Forty Seven (FTSV) and Lannett (LCI).

News coverage about CNAT stock has trended somewhat positive on Monday, Accern reports. The research group ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Conatus Pharmaceuticals earned a daily sentiment score of 0.14 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 45.86 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Shares of CNAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CNAT stock can currently be purchased for approximately $4.18.

Conatus Pharmaceuticals has a market capitalization of $132.58 million and generates $35.38 million in revenue each year. The biotechnology company earns $-17,390,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis. Conatus Pharmaceuticals employs 35 workers across the globe.

Conatus Pharmaceuticals' mailing address is 16745 WEST BERNARDO DRIVE Suite 200, San Diego CA, 92127. The biotechnology company can be reached via phone at 858-376-2600 or via email at [email protected]